Clinical Studies

Summary of Study:

The trial aims to evaluate the tolerability and adverse event profile of VETIGEL in the setting of canine epistaxis of any cause. With this, we also are studying the potential hemostatic activity of VETIGEL in canine epistaxis. Canine epistaxis was found to be a result from a variety of causes, including trauma, foreign bodies, infections, coagulopathies, and neoplasia.

Initially, 18 dogs with epistaxis of any cause will be enrolled to assess the tolerability of VETIGEL. If 0/18 dogs tolerate VETIGEL applications, the study will stop. If VETIGEL is tolerated in ≥1 of the initial 18 dogs, a second cohort of 18 dogs will be recruited.

The trial aims to evaluate the tolerability and adverse event profile of VETIGEL in the setting of canine epistaxis of any cause. With this, we also are studying the potential hemostatic activity of VETIGEL in canine epistaxis. Canine epistaxis was found to be a result from a variety of causes, including trauma, foreign bodies, infections, coagulopathies, and neoplasia.

This is a prospective, observational, multicenter, pilot study.

Inclusion Criteria

We will consider any dog with active epistaxis, unilateral or bilateral, of any underlying cause, including those secondary to underlying pathology or secondary to nasal turbinate biopsy.

Interested?

Enroll or request more information below.